[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dme\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dme":15},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,61,90,114,135,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627538","phase-3-como-a-phase-3-randomized-double-masked-study-comparing-the-efficacy-of-eyp-1901-against-aflibercept-in-dme-100627538",false,"NCT07449936","COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)","DME","Inclusion Criteria:\n\n* Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit.\n* Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20\u002F200 Snellen equivalent) to 78 letters (20\u002F32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).\n* For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit.\n\nExclusion Criteria:\n\n* BCVA using ETDRS charts \\\u003C30 letters (20\u002F250 Snellen equivalent) in the fellow eye.","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.",[27,15,28],"Diabetic Macular Edema","Diabetic Macular Edema (DME)",[30,31,32,27],"EyePoint","EYP-1901","Tyrosine Kinase Inhibitor","RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-03","ACTUAL",{"date":39,"type":37},"2026-02-16",{"date":41,"type":21},"2028-10",{"name":43,"class":44},"EyePoint Pharmaceuticals, Inc.","INDUSTRY",65,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":25,"conditions":53,"keywords":54,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":60},"100627537","phase-3-capri-a-phase-3-randomized-double-masked-study-comparing-the-efficacy-of-eyp-1901-against-aflibercept-in-dme-100627537","NCT07449923","CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME",{"count":20,"type":21},[24],[27,15,28],[30,32,27,31],{"date":36,"type":37},{"date":57,"type":37},"2026-02-09",{"date":41,"type":21},{"name":43,"class":44},62,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100618219","ai-vs-physician-for-anti-vegf-decision-making-an-rct-100618219","NCT07328776","AI vs. Physician for Anti-VEGF Decision-Making: An RCT","An Artificial Intelligence System for Anti-VEGF Treatment Decisions in Retinal Diseases: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients with a diagnosis of nAMD, DME, and RVO; Patients who have completed the loading-dose treatment of anti-VEGF agents; Patients who were willing to participate and provided written informed consent.\n\nExclusion Criteria:\n\nRefusal to undergo OCT testing; Refusal to complete the 3-month follow-up period; Screening for a history of intraocular surgery within the past 6 months; Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc.","50 Years","85 Years",{"count":71,"type":21},200,[73],"NA","We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases. QiLin was trained and validated via over 20,000 optical coherence tomography images from multicenter datasets, demonstrating strong performance on both internal and external validation. To evaluate its real-world clinical utility, we conducted a randomized controlled trial that rigorously compares the accuracy of treatment decisions between a physician-only arm and an AI-assisted physician arm.",[15,76,77],"Retinal Vein Occlusion (RVO)","Neovascular (Wet) Age-Related Macular Degeneration","NOT_YET_RECRUITING","2026-05-18",{"date":81,"type":37},"2026-05-22",{"date":83,"type":21},"2026-05-25",{"date":85,"type":21},"2026-10-15",{"name":87,"class":88},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100628299","phase-2-study-of-cu06-1004-in-patients-with-daibetic-macular-edema-100628299","NCT07459829","Study of CU06-1004 in Patients With Daibetic Macular Edema","A Phase 2b, Randomized, Double-masked, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of CU06-1004 for 24 Weeks in Patients With Center-Involved Diabetic Macular Edema (DME)","Inclusion Criteria:\n\nPatients will be eligible for inclusion in the study if they meet all of the following criteria:\n\n1. Have read, understood, and signed the informed consent form.\n2. Patient is willing and able to comply with all study procedures, and is likely to complete the study, based on the investigator's judgment.\n3. Male and female patients must be ≥18 years of age at the time of screening visit. Race and ethnicity information will be collected based on National Institutes of Health criteria.\n4. Has a diagnosis of Type 1 or Type 2 diabetes mellitus.\n5. Has definite retinal thickening due to DME in the center of the macula of the study eye (either treatment-naïve or previously treated patients).\n6. The study eye has a BCVA of 25 to 69 (approximate Snellen equivalent of 20\u002F50 to 20\u002F320) at an initial distance of 4 meters, as assessed by the ETDRS letter score at screening.\n7. Has a study eye with CST of ≥320 µm for men or ≥305 µm for women as determined by Heidelberg Spectralis (or equivalent) SD-OCT (or Zeiss Cirrus OCT: 305 µm for men or 290 µm for women) and confirmed by the CRC at screening.\n8. Has a DRSS score of ≥43 confirmed by the CRC.\n9. Has media clarity, pupillary dilation, and patient cooperation sufficient for adequate fundus photographs.\n10. Is willing to abide by the contraceptive requirements.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n1. Has only 1 functional eye, even if the eye met all other study requirements, or has and\u002For is likely to have amblyopia, amaurosis, or an ocular disorder with BCVA ≤25 ETDRS letter score (approximate Snellen equivalent of \\\u003C20\u002F320) in the fellow eye.\n2. Concurrent and\u002For history (where indicated) of an ocular condition including one or more of the following in the study eye:\n\n   1. Active proliferative diabetic retinopathy (PDR) or preretinal fibrosis involving the macula.\n\n      Note: Patients with mild PDR without high-risk features will be allowed in the study.\n   2. Vitreomacular traction or epiretinal membrane that is expected to affect central vision.\n   3. Iris neovascularization, vitreous hemorrhage, or tractional retinal detachment.\n   4. Uncontrolled glaucoma or filtration surgery for glaucoma in the past or likely to be needed in the future\n   5. Intraocular pressure (IOP) \\>24 mmHg at screening and randomization. IOP will be assessed by applanation tonometry (Goldmann tonometer, Tono-pen™, or an equivalent device).\n   6. Spherical equivalent of the refractive error of more than 6 diopters myopia or any signs of myopic chorioretinopathy.\n   7. Structural damage to the center of the macula that is likely to preclude improvement in BCVA following the resolution of macular edema, including atrophy of the RPE, subretinal fibrosis or scar, significant macular ischemia, or organized hard exudates.\n   8. Disease other than DME, that could compromise visual acuity, require medical or surgical intervention during the study period, or could confound interpretation of the results (including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause) as assessed by the investigator.\n   9. Macular edema is of nondiabetic retinopathy etiology (eg, secondary to vitreomacular interface abnormalities).\n   10. Inability to obtain fundus and OCT images due to, but not limited to, insufficient media clarity or inadequate pupil dilation.\n   11. Aphakia or absence of the posterior capsule. Absence of an intact posterior capsule is allowed if it occurred because of Yttrium-aluminum-garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation longer than 2 months before screening.\n3. Concurrent and\u002For history (where indicated) of ocular condition including one or more of the following in either eye:\n\n   1. There is evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis. However, a patient who has completely recovered from the infection at Week 1 (baseline) is allowed to be enrolled in the study at the investigator's discretion.\n   2. Has any active intraocular inflammatory disease such as uveitis or a history of intraocular inflammatory disease other than what would be expected in the normal postoperative course following prior routine ocular surgery such as cataract surgery.\n4. Had major surgery within 3 months prior to randomization or has major surgery planned during the next 6 months.\n5. Had unstable angina, myocardial infarction, transient ischemic attack, cerebral infarction, coronary artery bypass surgery, or transluminal coronary angioplasty within 6 months before screening.\n6. Has the following illness or abnormal laboratory test values:\n\n   1. Persisting elevations of aspartate aminotransferase or alanine aminotransferase \\>2 × upper limit of normal (ULN)\n   2. Uncontrolled hypertension (systolic blood pressure of \\>180 mmHg or diastolic blood pressure of \\>100 mmHg).\n   3. Uncontrolled diabetes (hemoglobin A1c \\>12.0%).\n   4. Total bilirubin \\>1.5× upper limit of normal.\n   5. Positive results for HIV or hepatitis B or C viruses.\n   6. Other clinically significant abnormal laboratory values per the investigator's judgment.\n7. Has severe renal impairment, defined as an estimated glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m².\n8. Has an ocular condition (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (eg, vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, foveal atrophy, pigmentary changes, dense subfoveal hard exudates, or a nonretinal condition).\n9. Is expected to have no improvement of decreased visual acuity in the opinion of the investigator, even if macular edema is resolved (eg, foveal atrophy, abnormal pigmentation, dense subfoveal hard exudate).\n10. Have administered vaccinium myrtillus extract or calcium dobesilate within 2 weeks before randomization.\n11. Have a hypersensitivity to any excipients of the investigational product or similar class of drug and ingredient.\n12. A pregnant woman, lactating woman, or a female or male patient of childbearing potential who does not accept appropriate contraceptive measures for at least 6 months prior to the first dose of the study treatment (hormonal contraceptives, intrauterine contraceptive device, sterilization of spouse \\[eg, vasectomy, tubal ligation\\], double-barrier method \\[eg, combinational use of spermicides and condoms, diaphragm, contraceptive sponge, or FemCap\\], sexual abstinence).\n13. Has a medical condition that, in the opinion of the investigator, would preclude participation in the study (eg, unstable medical status including blood pressure, cardiovascular disease, and glycemic control or a significant medical condition including end-stage renal disease and severe liver diseases).\n\n    Patients with a study eye that meets any of the following criteria may not participate in this study:\n14. Has history of intravitreal (IVT) treatment with anti-VEGF agents prior to randomization: A 3-month washout for ranibizumab and bevacizumab, and a 4-month washout for aflibercept 2mg, (and 6 months for longer-acting agents such as faricimab or aflibercept 8mg) are required. Any patients with a history of prior brolucizumab use in the study eye will be excluded from this study.\n15. Has history of treatment with IVT or periocular triamcinolone acetonide or IVT dexamethasone within 12 months of screening or has received an IVT dexamethasone implant (Ozurdex), or fluocinolone acetonide implant (Iluvien) or Susvimo (ranibizumab) implant any time prior to randomization.\n16. Has history of panretinal scatter photocoagulation (PRP) or is anticipated to require PRP in the 3 months following randomization.\n17. Has history of focal laser treatment (focal\u002Fgrid laser photocoagulation) within 3 months prior to randomization and\u002For focal laser scar in the fovea that could limit BCVA improvement in the study eye.\n18. Has history of ocular surgery (including cataract extraction, any intraocular surgery, etc) within 3 months prior to screening or anticipated within the next 6 months following randomization.\n19. Has history of retinal detachment or retinal detachment repair surgery.\n20. Has history of vitrectomy.\n21. Participation in another interventional clinical trial for DME in either eye within 90 days before screening or any previous participation in a clinical trial of systemic antiangiogenic drugs with receipt of a previous study drug within 180 days before screening or 5 times the half-life of the study drug used, whichever is longer.",{"count":98,"type":21},156,[100],"PHASE2","This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).",[15,27,28],[27,15,104],"endothelial dysfunction blocker","2026-03-03",{"date":107,"type":37},"2026-03-10",{"date":109,"type":21},"2026-12-01",{"date":111,"type":21},"2028-01-30",{"name":113,"class":44},"Curacle Co., Ltd.",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100608301","phase-2-a-phase-2a-study-to-evaluate-the-safety-tolerability-and-efficacy-of-snp318-in-dme-patients-100608301","NCT07199777","A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients","A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema","Main Inclusion Criteria:\n\n1. Confirmed diabetes mellitus Type 1 or Type 2, with stable glycemic control\n2. Center-involved DME with CST \\>=320 µm (Study eye)\n3. BCVA between 82 and 25 letters, inclusive (Study eye)\n4. BCVA score ≥ 25 letters (Non-study eye)\n\nMain Exclusion Criteria:\n\n1\\. Use of the last intravitreal anti-VEGF injection in the study eye within 90 days prior to Screening",{"count":122,"type":21},60,[100],"The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.",[27,15],"2025-09-22",{"date":128,"type":37},"2025-09-30",{"date":130,"type":21},"2025-11",{"date":132,"type":21},"2027-03",{"name":134,"class":44},"SciNeuro",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":17,"minAge":142,"maxAge":68,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100585323","the-effect-of-bulk-filling-flowable-composite-on-caries-recurrence-in-deep-marginal-elevation-a-randomized-clinical-trial-100585323","NCT06900868","The Effect of Bulk Filling Flowable Composite on Caries Recurrence in Deep Marginal Elevation: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults patients (20-50)\n* Good oral hygiene (plaque index 0 or 1 )\n* Patient approving to participate in the study\n* Absence of parafunctional habits and\u002For bruxism\n* No sign of irreversible pulpitis\n* No periapical radiolucency\n* Deep subgingival margin\n* Molars class II with subgingival margin\n\nExclusion Criteria:\n\n* • Patients with known allergic or adverse reaction to the tested materials.\n\n  * Systematic disease that may affect participation.\n  * Xerostomic patients.\n  * Bad oral hygiene (plaque index 2 or 3 )\n  * Heavy smokers\n  * Patients undergoing or will start orthodontic treatment\n  * Patients with removable prothesis",true,"20 Years",{"count":144,"type":21},50,[73],"Deep marginal elevation usinge a bioactive dental material in deep subgingival Class II restorations, S-PRG filler-containing materials offer significant benefits due to their bioactive properties, Their ability to release fluoride, remineralization potential and acid neutralization, reducing the risk of recurrent caries, particularly at the gingival margin(Imazato et al. 2023). The antibacterial and antifungal effects help inhibit biofilm formation, enhancing the longevity of restorations. Additionally, these materials support better marginal adaptation by reducing microleakage and improving bond durability (Imazato et al. 2023) This type of composite may improve the outcomes of deep subgingival margin elevation, benefiting both restorative success and periodontal health(Imazato et al. 2023).",[15,148,149,150],"Dental Caries","Dental","Deep Margin Elevation",[152],"Deep margin elevation","2025-03-22",{"date":155,"type":37},"2025-03-28",{"date":157,"type":21},"2025-03-20",{"date":159,"type":21},"2026-04-20",{"name":161,"class":88},"Future University in Egypt",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":141,"sex":17,"minAge":142,"maxAge":68,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100583378","clinical-performance-of-high-viscosity-bioactive-injectable-composite-in-deep-marginal-elevation-100583378","NCT06875544","Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation","Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation Randomized Controlled Trail","Randomized","Inclusion Criteria:\n\n1. Adult Patient (20-50 years old)\n2. Good oral hygiene (plaque index 0 or 1)\n3. Patient approval\n4. Absence of parafunctional habits and\u002For bruxism\n5. No endodontic treatment\n6. No abscess\n7. No partial or fixed denture\n\nExclusion Criteria:\n\n1. Patients with known allergic or adverse reaction to the tested materials.\n2. Bad oral hygiene\n3. Systematic disease that may affect participation.\n4. Xerostomic patients.\n5. Patients with active periodontal disease.\n6. Heavy smokers (those who smoke greater than or equal to 25 or more cigarettes a day)\n7. Orthodontic treatment patient",{"count":144,"type":21},[73],"Using a bioactive resin composite in subgingival Class II cavities can provide enhanced caries resistance by releasing multiple ions, including fluoride. This approach offers greater resistance to caries due to the incorporation of surface pre-reacted glass filler (S-PRG) technology (Imazato, Nakatsuka et al., 2023).\n\nThis type of composite may improve the outcomes of deep subgingival margin elevation, benefiting both restorative success and periodontal health.",[15,149,150],[175],"deep margin elevation","2025-03-08",{"date":178,"type":37},"2025-03-13",{"date":180,"type":21},"2025-03",{"date":182,"type":21},"2026-04",{"name":161,"class":88}]